Bimonthly, Established in 1959
Open access journal

adhd medications

Adult ADHD Prevalence Reaches Critical Levels: 2025 Statistics Reveal Public Health Challenge

Attention-Deficit/Hyperactivity Disorder (ADHD) is no longer considered a childhood-limited condition, with new data confirming significant diagnostic prevalence among adults worldwide. According to 2025 projections extrapolated from the latest Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) and CHADD analyses, approximately 16.13 million U.S. adults (6.2% of the adult population) and…

Transitioning Adolescents with ADHD to Adult Care

Transitioning Adolescents with ADHD to Adult Care: Strategic Medication Selection Mitigating Substance Risks in College Through Non-Stimulant Alternatives Introduction: Navigating a Critical Developmental Crossroad The transition from pediatric to adult healthcare services represents one of the most vulnerable periods for adolescents with attention-deficit/hyperactivity disorder (ADHD). Nearly 70% of childhood ADHD cases persist into adulthood, yet…

ADHD: Symptoms and Diagnosis Across the Lifespan

ADHD: Symptoms and Diagnosis Across the Lifespan Abstract Attention-Deficit/Hyperactivity Disorder (ADHD) is no longer conceptualized as a childhood-limited condition. By 2025, research confirms that neurodevelopmental trajectories significantly influence symptom expression from infancy to late adulthood. This review synthesizes updated diagnostic criteria (ICD-11), CDC epidemiological surveillance data (2023-2024), and clinical management strategies across life stages, highlighting…

ADHD Medications

A Practical, Plain-English Guide to ADHD Medications (2025) By the Shanghai Archives of Psychiatry blog team – last updated 2 June 2025 Few topics in mental-health care generate as many urgent late-night searches as “Which ADHD medicine is right for me (or my child)?” You open a browser and tumble into a warren of brand…

Strattera

Strattera Why Single Out Strattera? Strattera® (generic name atomoxetine) was the first non-stimulant granted FDA approval for attention-deficit/hyperactivity disorder (ADHD) in both children and adults (2002). Its unique status matters for three common clinical scenarios: Comorbid tics – atomoxetine does not aggravate motor or vocal tics, whereas stimulants occasionally can. Prominent anxiety – it raises…